期刊文献+

血清前列腺特异性抗原与碱性磷酸酶测定在判断前列腺癌骨转移中的价值 被引量:4

Relationship of Serum Prostate-specific Antigen and Alkaline Phosphatase Levels with Bone Metastases in Patients with Prostate Cancer
下载PDF
导出
摘要 目的:探讨血清前列腺特异性抗原(PSA)和碱性磷酸酶(ALP)水平与前列腺癌骨转移的关系。方法:回顾性分析96例前列腺癌患者的临床资料(其中29例伴有骨转移,67例不伴有骨转移)及患者血清PSA、ALP水平和骨扫描情况。结果:骨扫描阳性患者的血清PSA和ALP平均浓度均明显高于骨扫描阴性者(P<0.01)。PSA>20μg/L时骨扫描的阳性率明显高于PSA<20μg/L时骨扫描的阳性率(P<0.01)。ALP>90 U/L时骨扫描的阳性率明显高于ALP<90 U/L时骨扫描的阳性率(P<0.01)。结论:伴有骨转移的前列腺癌患者血清PSA和ALP水平均明显高于无骨转移者。当血清PSA>20μg/L和(或)ALP>90 U/L时应行骨扫描检查。 Objective: To investigate the relation of serum prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels to bone metastases in patients with prostate cancer. Methods : We made a retrospective study of 96 cases of prostate cancer with (29 cases ) and without (67 cases ) bone metastases and evaluated their initial levels of serum PSA and ALP as well as the radionuclide bone scan findings. Results: The median concentrations of serum PSA and ALP were both in the bone scan-positive patients statistically higher than in those the negative ones (P 〈 0.01 ). The percentages of the bone scan-positive patients with PSA 〉 20 μg/L or ALP 〉 90 U/L were also higher than those with PSA 〈 20 μg/L or ALP 〈 90 U/L ( P 〈 0.01 ). Conclusion : Prostate cancer patients with bone metastases have higher levels of PSA and ALP than those without. Radionuclide bone scan is necessary when the serum PSA level is 〉20 μg/L and/or ALP level 〉90 U/L. Natl J Androl,2005,11(11) :825-827
出处 《中华男科学杂志》 CAS CSCD 2005年第11期825-827,共3页 National Journal of Andrology
关键词 前列腺癌 前列腺特异性抗原 碱性磷酸酶 骨扫描 骨转移 prostate cancer prostate-specific antigen alkaline phosphatase radionuclide bone scan bone metastasis
  • 相关文献

参考文献6

  • 1Ballentine Carter H, Partin AW. Diagnosis and staging of prostate cancer. In: Walsh PC, Retic AB, Vaughan ED Jr, et al. Campbell's Urology[M].Vol 3. 7th ed. Philadelphia: WB Saunders,1998.2530-2531.
  • 2Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer[J]. JAMA, 1993, 269(1):57-60.
  • 3Wymenga LF, Boomsma JH, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase[J]. BJU Int, 2001, 88(3):226-230.
  • 4Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer:prostate specific antigen in superior to all other clinical parameters[J]. J Urol, 1991, 145(2):313-318.
  • 5Lorente JA, Valenzuela H, Morote J, et al. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate[J]. Eur J Nucl Med, 1999, 26(6):625-632.
  • 6Stokkel MP, Zwinderman AH, Zwartendijk J, et al. The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma[J]. Int J Biol Markers, 1998, 13(2):70-76.

同被引文献35

  • 1Katsuyoshi Tamaki,Ichiro Shimizu,Mari Urata,Nao Kohno,Hiroshi Fukuno,Susumu Ito,Nobuya Sano.A patient with spinal metastasis from hepatocellular carcinoma discovered from neurological findings[J].World Journal of Gastroenterology,2007,13(19):2758-2760. 被引量:2
  • 2胥林波.腰椎间盘突出症的诊治误区及对策[J].中国针灸,2007,27(6):459-461. 被引量:2
  • 3孙程,胡志伟.骨转移癌误诊为腰椎间盘突出症10例分析[J].临床误诊误治,2007,20(6):35-35. 被引量:3
  • 4Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results, Clin Exp Metastasis, 2003, 20 ( 2 ) : 171-180.
  • 5Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med, 2008, 75 (10): 739 -750.
  • 6Yi B, Williams PJ, Niewolna M, et al. Tumor-derived plateletderived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.Cancer Res, 2002, 62(3): 917-923.
  • 7Drake MT, Clarke BL, Kholsa S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc, 2008, 83 (9) : 1032-1045.
  • 8Wada N, Fujisaki M, Ishii S, et al. Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer, 2001, 8(2) : 131-137.
  • 9Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum Pathol, 2000, 31(5): 578-583.
  • 10Chen N, Ye XC, Chu K, et al. A secreted isoform of ErbB3 promotes osteoneetin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res, 2007, 67 (14) : 6544- 6548.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部